Moderna COVID-19 vaccine can produce immune response against coronavirus

Share

According to the same World Health Organization document, the only vaccine candidates to have reached Phase III trials were the University of Oxford/Astra Zeneca's and China's Sinovac's.

"The mRNA-1273 vaccine-induced anti-SARS-CoV-2 (coronavirus) immune responses in all participants, and no trial-limiting safety concerns were identified".

However, there was no further information on when this vaccine would enter the commercial production stage.

Worldwide, according to a New York Times report, a total of 155 vaccines are in different stages of development, of which 22 have reached human trial stage, with Bharat Biotech's "Covaxine" being one among them.

The results are from an early Phase 1 study that was designed to test low, medium and high doses of the vaccine and to gauge their safety and ability to create immunity to the virus. "The soonest we will launch industrial production is in the fall, only if all phases of trials go perfectly well".

With a phase 2 clinical trial of mRNA-1273, beginning enrolment in late May, the researchers said plans are now underway to launch a Phase 3 efficacy trial this month.

Sreekumar said that global vaccines can come to India, but the drug regulator may ask for clinical trials on Indian population before giving a marketing approval.

In a posting on ClinicalTrials.gov, Moderna said the trial is expected to begin on July 27.

Читайте также: UM supports Harvard lawsuit seeking to stop deportation of some global students

The ongoing Phase 1 trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

But some in the scientific community said they would reserve judgment until they saw the full results in peer-reviewed form.

According to the report, Tarasov said the first group of volunteers would be discharged on July 15 and the second group on July 20. The country saw the highest number of recovered patients in a single day with 20,572 patients declared free of COVID-19. According to the researchers, side-effects found in the patients are not severe that it will hamper further research.

However, more than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site.

Three participants did not receive their second dose.

However, Heaton added, "we must bear in mind the complexity of vaccine development and the work still to be done before COVID-19 vaccines are widely available".

"The results look pretty good and look pretty consistent", David Lo, a professor of biomedical sciences at University of California Riverside told AFP.

"The safety of the vaccine is confirmed".

При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.

Код для вставки в блог

Share